Bone-vascular cross-talk

Journal of Nephrology

Volumn 25, Issue 5, 2012, Pages 619-625

  London, Gérard M ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Arteries; Calcifications; Inflammation; Osteopenia; Osteoporosis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BONE MORPHOGENETIC PROTEIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR MSX2; WNT PROTEIN;

AGING; ALCOHOL CONSUMPTION; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BONE BLOOD FLOW; BONE REMODELING; CELL FUNCTION; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; INFLAMMATION; KIDNEY FAILURE; MENOPAUSE; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; OSTEOBLAST; OSTEOPENIA; OSTEOPOROSIS; OXIDATIVE STRESS; RENAL OSTEODYSTROPHY; RISK FACTOR; SIGNAL TRANSDUCTION; SMOKING;

BONE AND BONES; BONE DISEASES, METABOLIC; BONE REMODELING; CARDIOVASCULAR DISEASES; CELL COMMUNICATION; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SIGNAL TRANSDUCTION; VASCULAR CALCIFICATION;

EID: 84866989781     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000187     Document Type: Article

References (91)

1. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996;27(3):394-401.
2. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20): 1478-1483.
3. Guérin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15(7):1014-1021.
4. Doherty TM, Asotra K, Fitzpatrick LA, et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA. 2003; 100(20):11201-11206.
5. Hayden MR, Tyagi SC, Kolb L, et al. Vascular ossification - calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis - calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol. 2005;4(1):1-22.
6. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95(6):560-567.
7. Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol. 2006;26(7):1423-1430.
8. Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM. Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? Kidney Int. 2008;73(4):384-390.
9. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol. 2010;7(9):528-536.
10. Neven E, De Schutter TM, De Broe ME, D'Haese PC. Cell biological and physicochemical aspects of arterial calcification. Kidney Int. 2011;79(11):1166-1177.
11. Sumino H, Ichikawa S, Kasama S, et al. Elevated arterial stiffness in postmenopausal women with osteoporosis. Maturitas. 2006;55(3):212-218.
12. Sumino H, Ichikawa S, Kasama S, et al. Relationship between brachial arterial endothelial function and lumbar spine bone mineral density in postmenopausal women. Circ J. 2007;71(10):1555-1559.
13. London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008;19(9):1827-1835.
14. Joki N, Hase H, Shiratake M, Kishi N, Tochigi S, Imamura Y. Calcaneal osteopenia is a new marker for arterial stiffness in chronic hemodialysis patients. Am J Nephrol. 2005;25(3): 196-202.
15. Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P. Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients. Hypertension. 2007;49(6):1278-1284.
16. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant. 2008;23(2):586-593.
17. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PW. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int. 2001;68(5):271-276.
18. Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol. 2000;20(8): 1926-1931.
19. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab. 2004;89(9):4246-4253.
20. Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005;20(11):1912-1920.
21. Hamerman D. Osteoporosis and atherosclerosis: biological linkage and the emergence of dual-purpose therapies. QJM. 2005;98(7):467-484.
22. Carr JJ, Register TC, Hsu F-Ch, et al. Calcified atherosclerotic plaque and bone mineral density in type 2 diabetes: the diabetes heart study. Bone. 2008;42(1):43-52.
23. Naves M, Rodríguez-García M, Díaz-López JB, Gómez-Alonso C, Cannata-Andía JB. Progression of vascular calcifications associated with greater bone loss and increased bone fractures. Osteoporos Int. 2008;19(8):1161-1166.
24. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15(7):1943-1951.
25. Adragao T, Herberth J, Monier-Faugere M-C, et al. Low bone volume-a risk factor for coronary calcifications in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(2):450-455.
26. Rodríguez-García M, Gómez-Alonso C, Naves-Díaz M, Diaz-Lopez JB, Diaz-Corte C, Cannata-Andía JB; Asturias Study Group. Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transplant. 2009;24(1):239-246.
27. Barreto DV, Barreto FC, Carvalho AB, et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int. 2005;67(4):1576-1582.
28. Osako MK, Nakagami H, Koibuchi N, et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res. 2010;107(4):466-475.
29. Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cells and bone cell differentiation. Arterioscler Thromb Vasc Biol. 1997;17:680-687.
30. Parhami F, Garfinkel A, Demer LL. Role of lipids in osteoporosis. Arterioscler Thromb Vasc Biol. 2000;20(11):2346-2348.
31. Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med. 2001;31(4):509-519.
32. Demer L, Tintut Y. The roles of lipid oxidation products and receptor activator of nuclear factor-êB signaling in atherosclerotic calcification. Circ Res. 2011;108(12):1482-1493.
33. Gerdhem P, Obrant KJ. Effects of cigarette-smoking on bone mass as assessed by dual-energy X-ray absorptiometry and ultrasound. Osteoporos Int. 2002;13(12):932-936.
34. Koh JM, Khang YH, Jung CH, et al. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre-and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos Int. 2005;16(10):1263-1271.
35. Wang M, Monticone RE, Lakatta EG. Arterial aging: a journey into subclinical arterial disease. Curr Opin Nephrol Hypertens. 2010;19(2):201-207.
36. Nakano-Kurimoto R, Ikeda K, Uraoka M, et al. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am J Physiol Heart Circ Physiol. 2009;297(5):H1673-H1684.
37. Burton DG, Matsubara H, Ikeda K. Pathophysiology of vascular calcification: Pivotal role of cellular senescence in vascular smooth muscle cells. Exp Gerontol. 2010;45(11):819-824.
38. Davies MR, Lund RJ, Mathew S, Hruska KA. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol. 2005;16(4):917-928.
39. Shao J-S, Cheng S-L, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005;115(5):1210-1220.
40. Al-Aly Z, Shao J-S, Lai C-F, et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-α-dependent signals in diabetic Ldlr-/-mice. Arterioscler Thromb Vasc Biol. 2007; 27(12):2589-2596.
41. Towler DA, Shao J-S, Cheng S-L, Pingsterhaus JM, Loewy AP. Osteogenic regulation of vascular calcification. Ann N Y Acad Sci. 2006;1068(1):327-333.
42. Cannata-Andia JB, Roman-Garcia P, Hruska K. The connections between vascular calcification and bone health. Nephrol Dial Transplant. 2011;26(11):3429-3436.
43. Boström KI, Rajamannan NM, Towler DA. The regulation of valvular and vascular sclerosis by osteogenic morphogens. Circ Res. 2011;109(5):564-577.
44. Shao JS, Cheng SL, Sadhu J, Towler DA. Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension. 2010;55(3):579-592.
45. Hjortnaes J, Butcher J, Figueiredo J-L, et al. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J. 2010;31(16):1975-1984.
46. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292(4):490-495.
47. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004;95(11):1046-1057.
48. Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260-1268.
49. Teitelbaum S L. Osteoclasts; culprits in inflammatory osteolysis. Arthritis Res Ther. 2006;8(1):201-208.
50. Byon CH, Sun Y, Chen J, et al. Runx2-upregulated receptor activator of nuclear factor êB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol. 2011;31(6): 1387-1396.
51. Panizo S, Cardus A, Encinas M, et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res. 2009;104(9):1041-1048.
52. Chitre M, Shechter D, Grauer A. Denosumab for treatment of postmenopausal osteoporosis. Am J Health Syst Pharm. 2011;68(15):1409-1418.
53. Helas S, Goettsch C, Schoppet M, et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol. 2009;175(2):473-478.
54. Schwartz AV. Diabetes mellitus: Does it affect bone? Calcif Tissue Int. 2003;73(6):515-519.
55. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 2007;22(9):1317-1328.
56. Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int. 2008;73(12):1345-1354.
57. Hofmann Bowman MA, Gawdzik J, Bukhari U, et al. S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol. 2011;31(2):337-344.
58. Tanikawa T, Okaya Y, Tanikawa R, Tanaka Y. Advanced glycation endproducts induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK and upregulation of Runx2. J Vasc Res. 2009;46:572-580.
59. Hamann C, Goettsch C, Mettelsiefen J, et al. Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. Am J Physiol Endocrinol Metab. 2011;301(6):E1220-E1228.
60. Alikhani M, Alikhani Z, Boyd C, et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone. 2007;40(2):345-353.
61. Valcourt U, Merle B, Gineyts E, Viguet-Carrin S, Delmas PD, Garnero P. Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem. 2007;282(8):5691-5703.
62. Griffith JF, Yeung DK, Tsang PH, et al. Compromised bone marrow perfusion in osteoporosis. J Bone Miner Res. 2008;23(7): 1068-1075.
63. Moe S, Drüeke T, Cunningham J, et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-1953.
64. Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011;22(1):124-136.
65. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15(11):2857-2867.
66. Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KI, O'Neill WC. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol. 2004;15(6): 1392-1401.
67. Hermans MM, Brandenburg V, Ketteler M, et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant. 2006; 21(5):1293-1299.
68. Scatena M, Liaw L, Ghiachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007;27(11):2302-2309.
69. Zhao M-M, Xu M-J, Cai Y, et al. Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo. Kidney Int. 2011;79(10):1071-1079.
70. Román-García P, Carrillo-López N, Fernández-Martín JL, Naves-Díaz M, Ruiz-Torres MP, Cannata-Andía JB. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone. 2010;46(1):121-128.
71. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011;109(6):697-711.
72. Huang JC, Sakata T, Pfleger LL, et al. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res. 2004;19(2):235-244.
73. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370-1378.
74. Kuro-o M. Klotho as a regulator of oxidative stress and senescence. Biol Chem. 2008;389(3):233-241.
75. Kawaguchi H, Manabe N, Miyaura C, Chikuda H, Nakamura K, Kuro-o M. Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J Clin Invest. 1999;104(3):229-237.
76. Suzuki H, Amizuka N, Oda K, Noda M, Ohshima H, Maeda T. Histological and elemental analyses of impaired bone mineralization in klotho-deficient mice. J Anat. 2008;212(3):275-285.
77. Desjardins L, Liabeuf S, Renard C, et al; on behalf of the European Uremic Toxin (EUTox) Work Group. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int. 2011. Epub ahead of print.
78. Bridgeman G, Brookes M. Blood supply to the human femoral diaphysis in youth and senescence. J Anat. 1996;188 (Pt 3):611-621.
79. Laroche M. Intraosseous circulation from physiology to disease. Joint Bone Spine. 2002;69(3):262-269.
80. Alagiakrishnan K, Juby A, Hanley D, et al. Role of vascular factors in osteoporosis. J Gerontol A Biol Sci Med Sci
81. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130(3):456-469.
82. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA. 2008;105(13):5266-5270.
83. Ferron M, Wei J, Yoshizawa T, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010;142(2):296-308.
84. Bacchetta J, Boutroy S, Guebre-Egziabher F, et al. The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease. Nephrol Dial Transplant. 2009; 24(10):3120-3125.
85. Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 2005;331(2): 520-526.
86. Luo XH, Guo LJ, Yuan LQ, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res. 2005;309(1):99-109.
87. Luo XH, Zhao LL, Yuan LQ, Wang M, Xie H, Liao EY. Development of arterial calcification in adiponectin-deficient mice: adiponectin regulates arterial calcification. J Bone Miner Res. 2009;24(8):1461-1468.
88. Maahs DM, Ogden LG, Kinney GL, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005;111(6):747-753.
89. Elefteriou F, Takeda S, Ebihara K, et al. Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA. 2004;101(9): 3258-3263.
90. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res. 2001;88(9):954-960.
91. Coen G, Ballanti P, Fischer MS, et al. Serum leptin in dialysis renal osteodystrophy. Am J Kidney Dis. 2003;42(5): 1036-1042.